{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:04:59Z","timestamp":1779311099282,"version":"3.51.4"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ceftaroline is increasingly prescribed for \u201coff-label\u201d indications involving longer durations and higher doses. There have been postmarketing case reports of neutropenia among patients who have received extended durations of ceftaroline, but limited published data currently exist on its incidence and risk factors. We review a total of 37 published cases of ceftaroline-associated neutropenia including cases (n = 4) identified in our health care system. The median time from ceftaroline initiation to development of neutropenia (range) was 25 (8\u2013125) days, with a median duration of neutropenia (range) of 4 (1\u201316) days. Agranulocytosis (absolute neutrophil count [ANC] nadir &amp;lt; 100 cells\/mm3) developed in 49% of cases (n = 18), and there was an ANC nadir of 0 in 27% (n = 10). The overall incidence of neutropenia among cases receiving ceftaroline for \u22657\u201314 days (range) was 12% (7%\u201318% per individual study), higher than for comparator antibiotics in the literature. Risk factors for ceftaroline-associated neutropenia varied among studies and remain poorly defined.<\/jats:p>","DOI":"10.1093\/ofid\/ofz168","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T10:10:42Z","timestamp":1553767842000},"source":"Crossref","is-referenced-by-count":14,"title":["Ceftaroline-Associated Neutropenia: Case Series and Literature Review of Incidence, Risk Factors, and Outcomes"],"prefix":"10.1093","volume":"6","author":[{"given":"Eva L","family":"Sullivan","sequence":"first","affiliation":[{"name":"Pharmacy Department, Scripps Mercy Hospital, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Brigg","family":"Turner","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Pacific University, Hillsboro, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Hollis R","family":"O\u2019Neal","sequence":"additional","affiliation":[{"name":"Pulmonary & Critical Care Medicine, Louisiana State University Health\/Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy F","family":"Crum-Cianflone","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Scripps Mercy Hospital, San Diego, California"},{"name":"Infectious Disease Division, Scripps Mercy Hospital, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"2020081003473910500_CIT0001","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020081003473910500_CIT0002","first-page":"263","article-title":"Bacteremia, sepsis, and infective endocarditis associated with Staphylococcus aureus","volume":"409","author":"Bergin","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"2020081003473910500_CIT0003","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40265-017-0785-2","article-title":"Early use of ceftaroline fosamil in the United States Veterans Health Care System","volume":"77","author":"Britt","year":"2017","journal-title":"Drugs"},{"key":"2020081003473910500_CIT0004","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","author":"Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2020081003473910500_CIT0005","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0006","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0007","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0008","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0009"},{"key":"2020081003473910500_CIT0010","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020081003473910500_CIT0011","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/AAC.00636-09","article-title":"In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003473910500_CIT0012","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00097-16","article-title":"Single- and repeated-dose pharmacokinetics of ceftaroline in plasma and soft tissues of healthy volunteers for two different dosing regimens of ceftaroline fosamil","volume":"60","author":"Matzneller","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003473910500_CIT0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archinte.159.6.607","article-title":"Incidence of beta-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis","volume":"159","author":"Olaison","year":"1999","journal-title":"Arch Intern Med"},{"key":"2020081003473910500_CIT0014","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2020081003473910500_CIT0015","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/phar.1596","article-title":"Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin","volume":"35","author":"Varada","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2020081003473910500_CIT0016","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003473910500_CIT0018","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/1060028016667583","article-title":"High incidence of adverse effects with extended use of ceftaroline","volume":"50","author":"Dellabella","year":"2016","journal-title":"Ann Pharmacother"},{"key":"2020081003473910500_CIT0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2020081003473910500_CIT0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaip.2016.03.008","article-title":"Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort","volume":"4","author":"Blumenthal","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020081003473910500_CIT0021","author":"TEFLARO"},{"key":"2020081003473910500_CIT0022","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/IPC.0000000000000470","article-title":"Telavancin for MRSA endocarditis: case report and review of the literature","volume":"25","author":"Majumdar","year":"2017","journal-title":"Infect Dis Clin Pract"},{"key":"2020081003473910500_CIT0023","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jcpt.12062","article-title":"Ceftaroline - a cause for neutropenia","volume":"38","author":"Rimawi","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2020081003473910500_CIT0024","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"2020081003473910500_CIT0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14740\/jmc2489w","article-title":"Ceftaroline-induced agranulocytosis","volume":"7","author":"Sahar","year":"2016","journal-title":"J Med Cases"},{"key":"2020081003473910500_CIT0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.14740\/jh281w","article-title":"Agranulocytosis secondary to ceftaroline use: a case report and review of the literature","volume":"5","author":"Phull","year":"2016","journal-title":"J Hematol"},{"key":"2020081003473910500_CIT0027","article-title":"Fever, rash and agranulocytosis","author":"Khan","journal-title":"BMJ Case Rep"},{"key":"2020081003473910500_CIT0028","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jac\/dkx452","article-title":"Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline","volume":"73","author":"Turner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020081003473910500_CIT0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","author":"Zasowski","year":"2017; : 10.1128\/.02015-16","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003473910500_CIT0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archsurg.1989.01410110067013","article-title":"Neutropenia complicating parenteral antibiotic treatment of infected nonunion of the tibia","volume":"124","author":"McCluskey","year":"1989","journal-title":"Arch Surg"},{"key":"2020081003473910500_CIT0031","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/379519","article-title":"Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam","volume":"37","author":"Peralta","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020081003473910500_CIT0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.30.4.375","article-title":"Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens","volume":"30","author":"Steed","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2020081003473910500_CIT0033","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14740338.2017.1376645","article-title":"Non-chemotherapy drug-induced neutropenia - an update","volume":"16","author":"Andr\u00e8s","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2020081003473910500_CIT0034","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/asheducation-2017.1.187","article-title":"Non-chemotherapy drug-induced neutropenia: key points to manage the challenges","volume":"2017","author":"Curtis","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2020081003473910500_CIT0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081003473910500_CIT0036","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bmj.288.6419.795","article-title":"Neutropenia due to beta lactamine antibodies","volume":"288","author":"Murphy","year":"1984","journal-title":"Br Med J"},{"key":"2020081003473910500_CIT0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/030098588802500305","article-title":"Cephalosporin-induced changes in the ultrastructure of canine bone marrow","volume":"25","author":"Deldar","year":"1988","journal-title":"Vet Pathol"},{"key":"2020081003473910500_CIT0038","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/AAC.31.11.1657","article-title":"Effects of beta-lactam antibiotics on proliferating eucaryotic cells","volume":"31","author":"Neftel","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081003473910500_CIT0039","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08104.x","article-title":"The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis","volume":"150","author":"Andr\u00e8s","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/5\/ofz168\/33576497\/ofz168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/5\/ofz168\/33576497\/ofz168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T07:00:59Z","timestamp":1721113259000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz168\/5421272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz168","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,3,28]]},"article-number":"ofz168"}}